Extracellular ATP drives systemic inflammation, tissue damage and mortality

Cell Death Dis. 2014 Mar 6;5(3):e1102. doi: 10.1038/cddis.2014.70.

Abstract

Systemic inflammatory response syndromes (SIRS) may be caused by both infectious and sterile insults, such as trauma, ischemia-reperfusion or burns. They are characterized by early excessive inflammatory cytokine production and the endogenous release of several toxic and damaging molecules. These are necessary to fight and resolve the cause of SIRS, but often end up progressively damaging cells and tissues, leading to life-threatening multiple organ dysfunction syndrome (MODS). As inflammasome-dependent cytokines such as interleukin-1β are critically involved in the development of MODS and death in SIRS, and ATP is an essential activator of inflammasomes in vitro, we decided to analyze the ability of ATP removal to prevent excessive tissue damage and mortality in a murine LPS-induced inflammation model. Our results indeed indicate an important pro-inflammatory role for extracellular ATP. However, the effect of ATP is not restricted to inflammasome activation at all. Removing extracellular ATP with systemic apyrase treatment not only prevented IL-1β accumulation but also the production of inflammasome-independent cytokines such as TNF and IL-10. In addition, ATP removal also prevented systemic evidence of cellular disintegration, mitochondrial damage, apoptosis, intestinal barrier disruption and even mortality. Although blocking ATP receptors with the broad-spectrum P2 purinergic receptor antagonist suramin imitated certain beneficial effects of apyrase treatment, it could not prevent morbidity or mortality at all. We conclude that removal of systemic extracellular ATP could be a valuable strategy to dampen systemic inflammatory damage and toxicity in SIRS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism*
  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Apoptosis
  • Apyrase / pharmacology
  • Cytokines / metabolism
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Endotoxins
  • Female
  • Hydrolysis
  • Inflammasomes / immunology
  • Inflammasomes / metabolism
  • Inflammation Mediators / metabolism*
  • Mice
  • Mice, Inbred C57BL
  • Mitochondria / immunology
  • Mitochondria / metabolism
  • Mitochondria / pathology
  • Purinergic P2 Receptor Antagonists / pharmacology
  • Signal Transduction
  • Suramin / pharmacology
  • Systemic Inflammatory Response Syndrome / chemically induced
  • Systemic Inflammatory Response Syndrome / immunology
  • Systemic Inflammatory Response Syndrome / metabolism*
  • Systemic Inflammatory Response Syndrome / pathology
  • Systemic Inflammatory Response Syndrome / prevention & control
  • Time Factors

Substances

  • Anti-Inflammatory Agents
  • Cytokines
  • Endotoxins
  • Inflammasomes
  • Inflammation Mediators
  • Purinergic P2 Receptor Antagonists
  • Suramin
  • endotoxin, Escherichia coli
  • Adenosine Triphosphate
  • Apyrase